Glyson-MF Tablet is a combination oral hypoglycemic agent containing Glipizide 5mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glipizide, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose production, contributing to enhanced glycemic control. This dual mechanism addresses both insulin secretion and insulin resistance, making Glyson-MF effective in patients inadequately controlled by diet, exercise, and monotherapy. It is recommended to initiate therapy with lifestyle modifications and adjust dosage based on glycemic response and tolerability. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, primarily attributed to Metformin. Hypoglycemia risk is increased due to Glipizide, necessitating careful monitoring, especially in elderly patients or those with renal impairment. Contraindications include diabetic ketoacidosis, severe renal or hepatic dysfunction, and hypersensitivity to components. Regular monitoring of blood glucose, renal function, and liver enzymes is advised during therapy. Glyson-MF should be used with caution during pregnancy and lactation. Patient adherence to prescribed dosage and lifestyle measures is critical for optimal therapeutic outcomes.